340 Heart failure and de novo human cardiogenesis

2004 ◽  
Vol 3 (1) ◽  
pp. 85-86
Author(s):  
B WOZNIEWICZ
Keyword(s):  
2015 ◽  
Vol 3 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Heli Tolppanen ◽  
Krista Siirila‐Waris ◽  
Veli‐Pekka Harjola ◽  
David Marono ◽  
Jiri Parenica ◽  
...  

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
S Abouradi ◽  
H Choukrani ◽  
A Maaroufi ◽  
A Drighil ◽  
R Habbal

Abstract Funding Acknowledgements Type of funding sources: None. INTRODUCTION STEMI gets complicated very often by a heart failure (HF), which it is important to know associated factors. The aim of this study  was to determinate the predictor factors of onset of de novo HF after STEMI in patients with no prior history of heart failure recorded at baseline. METHODS A retrospective, descriptive study from 1 center in Morocco, including 210 patients hospitalized in a cardiology intensive care unit for STEMI from September 2019 to November 2020. The main outcomes were HF Killip class at hospital presentation and intra-hospital mortality. RESULTS The main age was 59.3 ± 7.02 and Sex ratio: 2, 86. The incidence of de novo HF at admission was higher in women (40, 4% vs. 29.5%, [OR 1, 61; 95%, [CI] 0, 83-3, 11). Forty-nine point eight percent were in Killip≥ 2. The method of early revascularization was Thrombolysis in 82, 3% compared to primary coronary angioplasty without significant difference in onset of the novo HF. There was no association of age, comorbidities, delay to hospital presentation and coronary involvement with incidence of onset of de novo HF.  Women had higher mortality than men with the novo HF (28, 6% vs. 20.5%; OR: 1, 55; 95%). CONCLUSION  Gender has appeared associated to onset of de novo HF after STEMI with a superiority of the female sex after controlling for others factors described in the literature. Anterior studies have related this to the increased prevalence of microvascular disease in women predisposing them to heart failure after STEMI.


2021 ◽  
Vol 7 ◽  
Author(s):  
Wilson Matthew Raffaello ◽  
Joshua Henrina ◽  
Ian Huang ◽  
Michael Anthonius Lim ◽  
Leonardo Paskah Suciadi ◽  
...  

Heart failure is currently one of the leading causes of morbidity and mortality. Patients with heart failure often present with acute symptoms and may have a poor prognosis. Recent evidence shows differences in clinical characteristics and outcomes between de novo heart failure (DNHF) and acute decompensated chronic heart failure (ADCHF). Based on a better understanding of the distinct pathophysiology of these two conditions, new strategies may be considered to treat heart failure patients and improve outcomes. In this review, the authors elaborate distinctions regarding the clinical characteristics and outcomes of DNHF and ADCHF and their respective pathophysiology. Future clinical trials of therapies should address the potentially different phenotypes between DNHF and ADCHF if meaningful discoveries are to be made.


2018 ◽  
Vol 252 ◽  
pp. 122-127 ◽  
Author(s):  
Rafael Kuperstein ◽  
Robert Klempfner ◽  
Efrat Ofek ◽  
Elad Maor ◽  
Dov Freimark ◽  
...  

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Vesna Degoricija ◽  
Matias Trbušić ◽  
Ines Potočnjak ◽  
Bojana Radulović ◽  
Sanda Dokoza Terešak ◽  
...  

2018 ◽  
Vol 72 (2) ◽  
pp. 223-233 ◽  
Author(s):  
Colin R. Lenihan ◽  
Sai Liu ◽  
Anita Deswal ◽  
Maria E. Montez-Rath ◽  
Wolfgang C. Winkelmayer

Author(s):  
Ersilia M. DeFilippis ◽  
Jennifer H. Haythe ◽  
Mary Norine Walsh ◽  
Michelle M. Kittleson

Heart failure (HF) is a leading cause of morbidity and mortality in pregnant women in the United States. Although peripartum cardiomyopathy is the most common diagnosis for pregnant women with HF, women with preexisting cardiomyopathies and systolic dysfunction are also at risk as the hemodynamic demands of pregnancy can lead to decompensation, arrhythmia, and rarely death. The differential diagnosis of HF in pregnancy is broad and includes Takotsubo or stress cardiomyopathy, exacerbation of a preexisting cardiomyopathy, such as familial cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, or left ventricular noncompaction. This review will explore the implications of pregnancy in women with preexisting cardiomyopathies and de novo HF, risk assessment and preconception planning, decisions about contraception, the safety of HF medications and implantable cardioverter-defibrillators during pregnancy, pregnancy in women with left ventricular assist devices and following heart transplantation.


Sign in / Sign up

Export Citation Format

Share Document